Few corners of the market have been as prone to dealmaking over the last couple of years as the life sciences industry. Fueled by strong demand for innovation, the cyclical nature of patent cliffs, and substantial cash reserves among major players, the sector has consistently presented attractive opportunities for investors who can identify and capitalize on the right trends. Now, as US and global dealmaking stage a substantial rebound, and as the Fed prepares to cut rates, the industry may be on the verge of a ‘cascade of takeovers,’ says an industry source consulted by Investing.com.
Read the full article: Biotech Ripe for ‘Cascade of Dealmaking’ – Here Are the Top Companies to Watch //
Source: https://www.msn.com/en-ca/money/other/biotech-ripe-for-cascade-of-dealmaking-here-are-the-top-companies-to-watch/ar-BB1l84p5